$MSLE

Satellos Bioscience Inc.

No enriched coverage for $MSLE in the last 7 days.

No SEC Form 4 filings for $MSLE in the last 30 days.

High

Investment bank Leerink Partners recently released a research report, initiating coverage on biotechnology company Satellos Bioscience Inc. (stock symbol: MSLE) for the first time.

Investment bank Leerink Partners has initiated coverage on Satellos Bioscience Inc. (MSLE) with an "Outperform" rating and a $20 target price. This positive outlook by analysts highlights the biotechnology company's innovative technology platform. The report aims to provide professional research references for investors interested in Satellos Bioscience.